Kornimate/medical-research-clean huggingface dataset:
evaluation of fapi-pet in prostate cancer.

Conditions: Prostate Cancer

Summary: the investigators explore the biodistribution of fapi-pet expression in primary high-risk prostate cancer in men undergoing ralp and elnd and in men with metastatic pca about to start next generation antiandrogen.

this is an exploratory cohort study comprised of men with clinically localized or locally advanced high-risk prostate cancer (gg 3-5, ct2-ct3, nx, m0) managed by ralp and elnd and men with metastatic (mhspc or mcrpc) prostate cancer scheduled to start nht along clinical care pathway (e.g., apalutamide, enzalutamide) at hus helsinki university hospital and helsinki university, finland. men identified along routine clinical care as candidates for the study will be asked to consent. once consented, patients will undergo psma-pet imaging instead of conventional imaging (ct and bone scan) and experimental fapi-pet imaging. furthermore, biomarker samples will be obtained before and after treatment (surgery or novel antiandrogen) and surgical specimen will be processed for routine pathological evaluation and multiplex ihc studies. serum samples will be tested for pca biomarkers (e.g., psa, nse, cga) and cfdna. urine will be processed and extracellular vesicles (exosomes) isolated and markers of reactive stroma will be sought for. radical prostatectomy and novel hormonal treatment will be done according to current recommendations and guidelines in finland. postoperatively, patients will be followed with psa every six months. biochemical recurrence will be set at psa of 0.2 ug/l or higher.

Eligibility criteria:
inclusion criteria: men scheduled for radical prostatectomy * age over 18 years * gg 3-5, ct2-ct3, nx, m0 prostate cancer * no contraindication to psma - or fapi-pet * willing to undergo study related procedures (imaging and laboratory tests) men scheduled for novel antiandrogen * age over 18 years * gg2-5, ct2-4, n0-1, m1 * hormone sensitive or castration resistant prostate cancer exclusion criteria: * not willing or capable to undergo study related procedures

Keywords: pet psma fap radical prostatectomy novel antiandrogen enzalutamide apalutamide fapi exosome
elimination of prostate cancer treatment side effects using a nutraceutical

Conditions: Prostate Cancer

Summary: does nutraceutical n-111 lower the number of side effects occurring during adt + external beam radiation (ebr) prostate cancer treatment?

researchers will compare nutraceutical n-111 to a placebo (a look-alike substance that contains no active ingredients) and control group to see if n-111 works to alleviate side effects of prostate cancer treatment. participants will: take n-111 or a placebo by mouth every day for the duration of the adt + ebr therapy. fill out the self-evaluation reporting form weekly during ebr therapy and every three months during adt therapy to assess their symptoms or lack of symptoms. the patients will see a physician once a week during the ebr therapy and once every three months for the duration of the adt therapy.

Eligibility criteria:
inclusion criteria: * male undergoing treatment for prostate cancer with adt + ebr. exclusion criteria: * everyone else

Keywords: prostate cancer
prediction of outcome of interventional pain management

Conditions: Low Back Pain; Neck Pain; Chronic Pain

Summary: interventional pain management for back and neck pain is widely used, but the indications and relative merits of these techniques rest subject to discussion. this study aims to identify prognostic criteria for patients who might specifically benefit from interventional pain management. specifically, the nociceptive reflex threshold will be investigated, which is a measure of central sensibilisation and thus a potentially important prognostic factor.

interventional pain management is resource-intensive and carries non-negligible risks. not all patients profit equally from such procedures. for those who do not benefit, the risk of potential complications is futile, and the resources are wasted. therefore, a possibility to distinguish responding patients from non-responders would be important. central pain sensitization has been related to poor outcome, and electrical pain and reflex thresholds are a good measure of pain hypersensitivity at least in chronic low back pain. especially the nociceptive flexion reflex (nfr) threshold has been identified to correlate well with central pain hypersensibility. successful interventional pain treatment has been shown to reverse central hypersensibility as measured by the nfr threshold. nfr threshold, in contrast to pain threshold, seems to be a measure independent of psychological factors. thus the nfr threshold could give information independent of psychological factors in order to predict poor outcome of interventional pain management procedures. the study will be a prospective observational trial of diagnostic accuracy.

Eligibility criteria:
inclusion criteria: * patients with chronic low back or neck pain (duration \>3 months) * scheduled for the following interventions: epidural injection, facet block, medial branch block, facet radiofrequency denervation, spinal cord stimulator implantation exclusion criteria: * inability to understand the patient information or the study questionnaires * patients \<18 years old * patients with implanted pacemakers or defibrillators

Keywords: nociceptive flexion reflex interventional pain management
effectiveness of visceral manual therapy in bruxist patients

Conditions: Bruxism

Summary: objective: check the effectiveness of visceral manual therapy on bruxist patients design: experimental, analytical, longitudinal, prospective, randomized, single-blind study with a blinded evaluator. subjects: 68 subjects over 18 years old, with bruxism (diagnoses by a dentist). methods: subjects will be randomized into 2 groups: an experimental group (eg) to which a visceral manual technique will be applied and a control group (cg) to which a placebo manual technique will be administered. both groups will receive 2 interventions one week apart. the measurements will be made before and after the interventions, and a last measurement will be made one month after the last intervention. therefore, the patient will visit the center 3 times.


Eligibility criteria:
inclusion criteria: * subjects with bruxism diagnosed and referred by a dentist * age: older than 18 years-old. exclusion criteria: * recent craniofacial, mandibular or cervical trauma or fracture. * temporomandibular joint surgery. * acute pain due to other components of the masticatory system (caries, inflammation of the dental root). * abdominal surgery. * gastric ulcers. * gastritis. * previous or current gastric neoplasm. * neurological or systemic diseases. * pregnant, including the period of breastfeeding. * patients receiving chemotherapy or radiotherapy. * cognitive, psychosomatic or psychiatric illnesses that may affect the data obtained. * basic systemic disease of rheumatic origin (for example, arthritis, osteoarthritis, gout and psoriasis). * cerebrovascular and brain diseases. * arrhythmia and other cardiac problems. * implanted electronic devices. * drug or alcohol abuse, analgesic or sedative therapy, and use of medications that affect the central nervous system (for example, antidepressants, anxiolytics, and anticonvulsants). * patients who have previous experience with manual treatment of the diaphragm

Keywords: bruxism musculoskeletal manipulations physical therapy modalities autonomic nervous system
(cost) effectiveness study of exercise therapy in patients with peripheral arterial disease

Conditions: Intermittent Claudication

Summary: the purpose of this study is to determine if supervised exercise therapy in a physiotherapeutic setting, with or without therapy feedback, is more (cost-)effective than exercise therapy based on a 'go home and walk' advice without supervision, for patients with pad stage ii (fontaine).

exercise therapy (et) is considered to be the main conservative treatment for patients with intermittent claudication (ic) and is documented to be effective, especially when supervised. however, wide scale introduction of supervised et in the netherlands would lead to a substantial increase of health care costs compared to current practice, while the cost-effectiveness of supervised et is uncertain. et follows a pattern of short walking periods that induce discomfort of moderate intensity and short rest periods. the psychological, metabolic, and mechanical alterations that occur during exercise stimulate an adaptive response that ultimately reduces the symptoms. the optimal therapy regimen depends to a large extent on home-based exercises, which require discipline from the patient. currently, the main prescription for et for patients with ic in the netherlands is a single 'go home and walk' advice, without supervision or follow-up. there is no evidence to support the effectiveness of this advice and compliance is low. in studies comparing the 'go home and walk' advice to supervised et, a large advantage for supervised et was present. the inadequate use of the main conservative treatment for peripheral arterial disease (pad) contributes to a gradual progression of this condition, a decrease in quality of life, and an increasing number of vascular interventions. furthermore, with adequate et, hypertension, hypercholesterolemia, overweight, and diabetes, if present, is better regulated.

Eligibility criteria:
inclusion criteria: * pad stage ii * ankle-brachial index below 0.9 * maximal walking distance of 500 meters or less exclusion criteria: * prior et * previous peripheral vascular interventions * no insurance for physiotherapy * insufficient command of the dutch language * serious cardiopulmonary limitations (nyha-3-4) * previous amputation * psychiatric instability * other serious co-morbidity prohibiting physical training

Keywords: intermittent claudication exercise therapy therapy feedback accelerometer physiotherapy pad; peripheral arterial disease according to fontaine stage ii)
air optix plus hydraglyde multifocal daily/extended wear contact lenses

Conditions: Refractive Errors

Summary: the purpose of this post-market clinical follow-up (pmcf) study is to assess long term performance and safety of air optix plus hydraglyde multifocal soft contact lenses in a real-world setting when worn as daily wear or extended (overnight) wear.

this is a non-interventional/observational study designed as a retrospective chart review. study sites will identify charts within their existing databases in a fair and consistent manner, e.g., reviewing all eligible charts in reverse chronological order by year of baseline visit. the baseline visit will be defined as the first office visit where an eye care practitioner provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for the study or comparator contact lenses was released. subjects/charts meeting the eligibility criteria will be enrolled in the study.

Eligibility criteria:
key inclusion criteria: * best corrected visual acuity (bcva) of 20/25 snellen or better in each eye at baseline; * must have worn or be wearing air optix plus hydraglyde multifocal or biofinity multifocal for at least 1 year in a daily wear modality, or 3 years in an extended wear modality; * other protocol-defined inclusion criteria may apply. exclusion criteria: * any recurrent history or active anterior segment infection, inflammation or abnormality contraindicating regular contact lens wear at baseline; * use of systemic or ocular medications contraindicating regular contact lens wear at baseline and/or during the period of the retrospective chart collection; * slit lamp findings, including signs of pathological dry eye, that would contraindicate regular contact lens wear; * participation of the patient in a contact lens or contact lens care product trial during the period of the retrospective chart collection; * other protocol-defined exclusion criteria may apply.
using a computer-assisted prescription to decrease inappropriate use of plain abdominal radiography in emergency department

Conditions: Plain Abdominal Radiography

Summary: the aim of this study is to assess whether a computer-assisted prescription allows a reduction of the overall number of inappropriate par in emergency departments.


Eligibility criteria:
inclusion criteria: * patients aged 16 or more with a par. exclusion criteria: * refusal to participate
hematrate™ in the treatment of critical limb ischemia

Conditions: Critical Limb Ischemia; Ischemia

Summary: the primary objective of this study is to evaluate the performance of the hematrate™ blood filtration system in the treatment of critical limb ischemia. the primary endpoint measure is comparing the percentage of patients between the treatment arm and control arm who have freedom from major amputation, arterial intervention below the knee, and death through 12 months.


Eligibility criteria:
inclusion criteria: 1. critical limb ischemia in the study leg with ischemic rest pain and/or ulcer/minor tissue loss (rutherford 4 or 5) 2. previously failed an endovascular or surgical treatment of the study lower leg and is not being considered for additional intervention within the next 3 months or is unsuitable for revascularization exclusion criteria: 1. simultaneously participating in another investigational study (e.g., drug or device) 2. pregnant or breastfeeding, or planning to become pregnant within the next 12 months 3. major surgery (open cardiac, vascular, or abdominal procedure) within the past 90 days 4. endovascular intervention within the past 30 days 5. current dialysis, or expected to need dialysis within the next 12 months 6. previous above the ankle amputation in the study leg

Keywords: lower extremity peripheral arterial disease ischemia peripheral blood stem cell transplantation leukocytes, mononuclear transplantation, autologous
anti-pd-1 monoclonal antibody tislelizumab (bgb-a317) combined with or without anti-tigit monoclonal antibody ociperlimab (bgb-a1217) in participants with recurrent or metastatic esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: a study of tislelizumab (bgb-a317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (pd-l1) tumor area positivity (tap) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed diagnosis of esophageal squamous cell carcinoma (escc). 2. have progressive disease during or after first-line of systemic treatment for unresectable, locally advanced, recurrent or metastatic escc. 3. have measurable disease as assessed by response evaluation criteria in solid tumors (recist) v1.1. 4. have confirmed programmed cell death protein-ligand 1 (pd-l1) tumor area positivity (tap) ≥ 10% in tumor tissues tested by the central lab. 5. eastern cooperative oncology group (ecog) performance status score of 0 or 1. key exclusion criteria: 1. prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, t-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains, or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways. 2. participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta). 3. evidence of complete esophageal obstruction not amenable to treatment. 4. uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within 2 weeks after intervention). 5. has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc) or any investigational therapies within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug. or has received palliative radiation treatment or other local regional therapies within 14 days before the first dose of study drug. note: other protocol defined inclusion/exclusion criteria may apply.
icbt for cardiac anxiety in patients with nccp

Conditions: Non-cardiac Chest Pain; Cardiac Anxiety

Summary: non-cardiac chest pain (nccp) is a common condition that significantly affects patients' mental well-being, overall quality of life, and healthcare use. even after ruling out cardiac issues, many patients still worry about having an undiagnosed cardiac illness, leading to cardiac anxiety since no other explanation is provided. consequently, they avoid activities they believe might harm their heart, worsening their overall health and resulting in increased healthcare visits and societal costs. addressing cardiac anxiety through psychological interventions could help break this viscious cycle and enhance patient outcomes. internet-delivered cognitive behavioural therapy (icbt) can assist patients in reassessing their perceptions, emotions and behaviours in order to handle their chest pain and therby reduce their cardiac anxiety. the aim of this study is to evaluate the short- and long-term effects of a guided 8-week icbt program on cardiac anxiety, generalized anxiety, kinesiophobia, fear of body sensations, depressive symptoms, health-related quality of life, chest pain frequency and illness perception. also to examine how participants' personality traits influence the effectiveness of the icbt program. furthermore, to assess the cost-effectiveness of the icbt program compared to attention control. in addition, we will explore the perceptions of participants regarding the therapeutic alliance during the treatment.


Eligibility criteria:
inclusion criteria: * experience of non-cardiac chest pain * exhibiting cardiac anxiety (score ≥24 on the cardiac anxiety questionnaire, caq) exclusion criteria: * language difficulties * patients with no access to computer/tablet and/or internet * not able to perform physical activity/exercise due to physical constraints * severe psychological disorders or chronic somatic illness assessed to be requiring acute treatment or to hinder participation

Keywords: cardiac anxiety cognitive behavioural therapy internet-delivered noncardiac chest pain psychological distress cost-effectiveness therapeutic alliance
immobilization versus immediate motion after anterior submuscular ulnar nerve transposition

Conditions: Cubital Tunnel Syndrome

Summary: the goal of this study is to test the hypothesis that immediate elbow motion is safe after anterior submuscular ulnar nerve transposition, and will not result in disruption of the repaired flexor pronator origin, under which the nerve is placed. the advantages of immediate elbow motion after submuscular ulnar nerve transposition for performing activities of daily living and self-care are evident, however theoretical advantages include early "gliding" of the transposed ulnar nerve with a lower risk of nerve adhesions and subsequent traction neuritis, as well as improved blood flow and quicker, more complete, recovery of nerve function. a group of 44 consecutive patients that are determined to be candidates for anterior submuscular ulnar nerve transposition based on history, positive findings on physical examination, and confirmatory electrodiagnostic testing will be prospectively randomized to either immediate motion or long arm cast immobilization after surgery. all patients will be counseled about the two postoperative treatment options (immobilization followed by protected range of motion versus immediate range of motion), risks involved with each treatment protocol, postoperative follow-up and need for radiographs. if they choose not to participate, they will be treated by the same postoperative protocol currently used by the principal investigator: arm sling at rest for six weeks with intermittent active assisted range of motion exercises.


Eligibility criteria:
inclusion criteria: * candidates for anterior submuscular ulnar nerve transposition based on history, positive findings on physical examination, and confirmatory electrodiagnostic testing in mayo clinic arizona exclusion criteria: * pregnancy * patients who have had prior ulnar nerve surgery * patients with other documented neurogenic processes identified on electrodiagnostic studies (ie: peripheral neuropathy, cervical radiculopathy, carpal tunnel syndrome) * workman's compensation patients * subluxing ulnar nerve * elbow contracture or stiffness * negative electrodiagnostic studies
lumbar fusion compared with conservative treatment in patients with chronic low back pain: a meta-analysis

Conditions: Comparison Between Effectiveness of Lumbar Fusion and Conservative Treatment

Summary: * to determine the effect size of lumbar fusion measured by oswestry disability index and compared with conservative treatment in patients with chronic low back pain. * meta-analysis using fixed effect model synthesis method. * included studies were retrieved from medline and cochrane central databases since 1990.


Eligibility criteria:
inclusion criteria: * controlled randomized or non-randomized studies exclusion criteria: * not specified
brain-to-society diagnostic for prevention of childhood obesity and chronic disease

Conditions: Obesity

Summary: this multi-national program applies a breakthrough approach to childhood obesity called, brain-to-society (bts) diagnostic approach. in montreal, canada and palwal, india, the investigators will recruit two cohorts of 612 children (6 to 12 years; 306 boy/306 girls) where whole-of-society (wos) transformations are taking place (industrialized societal context with peaking childhood obesity and where a broad governmental plan to promote healthy lifestyle has been adopted -canada; developing societal context with increasing childhood obesity if replication of past pathways that have lead to double burden; india) are taking place along with world health assembly (wha) resolution a63-12 for marketing of food to children. individual-level bts diagnostic will examine the degree to which individual differences in genetics and biology and differences in the environmental exposures modulate the behavioral, body weight/fatness and nutritional risk over time in the context of wos transformations. societal-level bts diagnostic shall examine the influence of decisions in policy, investment, business and innovation made by different stakeholders (government, private sector, civil society in health and non-health society systems including agriculture, business and media practices) on the community.


Eligibility criteria:
inclusion criteria: * sample population that are exposed to multi-level whole-of-society transformation (i.e., quebec governmental action plan (pag) and world health assembly (wha) resolution for quebec sample; intense urbanization and industrialization (iui) and wha resolution in india). exclusion criteria: * first cousin relations were excluded from the sample population.

Keywords: childhood obesity body weight nutritional risk
comparison of feasibility between internal and external pancreatic drainage in pancreaticoduodenectomy

Conditions: Pancreatic Fistula

Summary: pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. to reduce pancreatic fistula, many authors recommend pancreatic stent in pancreatojejunostomy. there are two distinct methods of pancreatic stent insertion: internal stent and external stent. there was few studies comparing these methods in preventing pancreatic fistula. furthermore, its long-term effect was not known enough. the purpose of this study is to determine which is the best method in preventing pancreatic fistula and to investigate its long term clinical outcomes.


Eligibility criteria:
inclusion criteria: * patient who have malignant or benign disease which needs pancreatoduodenectomy * patient age: ≥20 and ≤85 exclusion criteria: * patient who had chemotherapy or radiotherapy previous to operation. * patient who had severe comorbid disease(cardiac, pulmonary, cerebrovascular) * patient who had past medical history of chronic pancreatitis. * pancreatic stent size \ 5mm

Keywords: pancreatic fistula pancreatic leakage pancreatoduodenectomy pancreatic stent